INTRODUCTION

Cell proliferation is the foundation of tumor development. Normally it follows an orderly progression through the cell cycle, which is controlled at specific checkpoints by a complex regulatory molecular system composed of cyclins and cyclin-dependent kinases (CDKs). One of the important checkpoints is the restriction point at the G1/S phase, at which the cell commits itself to another round of DNA synthesis and replication or remains in the resting phase. Among the various cyclins, cyclin D1 is implicated more in tumorigenesis.\(^1\)–\(^3\)

Cyclin D1, a 45 kd protein, a member of G1 cyclins, encoded by the CCND1 gene on chromosome 11q13, controls the cell-cycle transit from the G1 to S phase. It acts by forming a complex with either CDK4 or CDK6. This complex leads to phosphorylation of the pRb tumor suppressor protein which in turn releases members of the E2F family of transcription factors leading to unhindered progression of the cell to the S phase. Thus cyclin D1 is an essential molecule for the dividing cell to enter the DNA synthesis phase.\(^2\)
The deregulation and overexpression of cyclin D1 has been revealed in many tumors of diverse histogenesis and has been correlated with rapid growth and increased proliferative activity, histologic aggressiveness, tumor invasiveness, and poor prognosis.

Ameloblastoma is the most frequently encountered odontogenic tumor that exhibits different histologic patterns. It is known for its local invasiveness and a high tendency to recur. On the contrary, adenomatoid odontogenic tumor, a relatively rare tumor, is a benign, nonaggressive tumor with a limited growth and no tendency to recur.

It has been showed that cyclin D1 participates in cell proliferation both in normal and neoplastic odontogenic epithelium. We assessed the immunohistochemical expression of cyclin D1 as a proliferation marker to investigate whether the expression of this marker in ameloblastoma and adenomatoid odontogenic tumor correlates with the known behavior of these two benign neoplasms.

**MATERIALS AND METHODS**

**Tissues**

Previously diagnosed tissues of ameloblastoma and adenomatoid odontogenic tumors were obtained from the files of the department of Oral and Maxillofacial Pathology, SDM college of Dental sciences and hospital, Dharwad. There were 39 ameloblastomas, and 11 adenomatoid odontogenic tumors. Among 39 cases of ameloblastoma, 25 were follicular, 10 were plexiform, and 4 were of unicystic types. A total of 22 cases of follicular ameloblastoma showed focal squamous metaplastic changes. Focal granular cell changes were observed in three cases of follicular ameloblastoma. All cases were reviewed histologically using hematoxylin and eosin staining to confirm the diagnosis. A total of 10 cases of poorly differentiated oral squamous cell carcinoma served as positive controls and were taken for each batch of the staining procedure.

**Immunohistochemistry**

Immunohistochemical staining was performed using labeled streptavidin–biotin technique. Five micrometer sections were made from formalin-fixed paraffin embedded tissues blocks and taken onto silanized slides (SIGMA, USA). The sections were dewaxed in xylene and rehydrated in graded alcohols. Antigen retrieval was done by the pressure cooker method in a 10 mM citrate buffer (pH 6.0) for 2 minutes. Endogenous peroxidase activity was blocked by covering the tissue sections by 3% hydrogen peroxide for 15 minutes. Then the sections were incubated for 1 hour in a humidifying chamber with monoclonal anticyclin D1 antibody (clone DCS6, DAKO, Denmark) diluted to 1:50 in Tris buffered saline (TBS).

The sections were incubated with biotinylated link (secondary) antibody for 45 minutes. This is followed by incubation with streptavidin peroxidase for 30 minutes. The antigen antibody reactions were visualized with the chromogen DAB. Tris buffered saline was used instead of primary antibody in negative control tissue sections. The sections were washed and then lightly counterstained with Harris’s hematoxylin, dehydrated, and mounted with DPX.

**Interpretation of staining**

The presence of brown-colored end-product at the site of target antigen indicated positive staining. Immunostaining was further graded as 1 when there was mild staining, 2 for moderate, and 3 for intense staining. The interpretation was similarly used by Mate et al.

The localization of staining and cell types which showed immunostaining in both ameloblastoma and adenomatoid odontogenic tumors were also noted accordingly. All these observations were carried out by three observers to eliminate interobserver bias.

**Statistical analysis**

A rank sum two-sample test (Mann–Whitney test) was used for the statistical interpretation of the intensity of staining results in different types of ameloblastomas and also between ameloblastoma and adenomatoid odontogenic tumors. A P value of less than 0.05 was taken as statistically significant.

**RESULTS**

Most of the ameloblastoma cases (79.5%) and adenomatoid odontogenic tumor (63.3%) were positive for cyclin D1 expression [Table 1]. The immunoreactivity was predominantly concentrated in both nucleus and cytoplasm in ameloblastomas [Table 2] and only nuclear in adenomatoid odontogenic tumors.

In ameloblastomas, 3 cases showed intense staining (grade 3) [Figure 1], 12 cases showed moderate staining (grade 2) [Figure 2], and 16 cases showed mild staining (grade 1) [Figure 3] while in adenomatoid odontogenic tumors, 2 cases were moderately immunoreactive (grade 2) [Figure 4], and 5 were mild (grade 1).

Cyclin D1 staining was observed both in peripheral columnar or cuboidal cells and in central stellate reticulum-like cells in most of the ameloblastoma cases. The squamous metaplastic cells and granular cells were negative for cyclin D1 expression [Figure 5]. In adenomatoid odontogenic tumors, the immunoreaction was found more commonly in whorls.

The rank sum two-sample test (Mann–Whitney test) between staining intensities in different histologic groups of ameloblastomas and also between ameloblastoma and adenomatoid odontogenic tumors showed nonsignificant P value (P>0.005) [Tables 3 and 4].
In positive cases, the staining pattern was heterogeneous; the unstained cells formed a minor fraction and were admixed with the stained cells which formed a major fraction of the sections studied. In negative cases all the cells were unstained.

Table 1: Staining results of ameloblastoma and adenomatoid odontogenic tumor

| Localization                  | Total number of cases | Number of positive cases (%) | Number of negative cases (%) |
|-------------------------------|-----------------------|------------------------------|------------------------------|
| Ameloblastoma                 |                       |                              |                              |
| Follicular                    | 25                    | 19                           | 06                           |
| Plexiform                     | 10                    | 09                           | 01                           |
| Unicytic                      | 04                    | 03                           | 01                           |
| Total                         | 39                    | 31 (79.5)                    | 08 (20.5)                    |
| Adenomatoid odontogenic tumor | 11                    | 07 (63.3)                    | 04 (37.7)                    |

Table 2: Total number of ameloblastoma cases showing the cyclin D1 immunolocalization

| Localization                  | Total |
|-------------------------------|-------|
| Nuclear                       | 2     |
| Nuclear and cytoplasmic       | 19    |
| Cytoplasmic                   | 10    |
| Total                         | 31    |
Cyclin D1 in ameloblastoma and AOT

Kumar, et al. 286

Table 3: Statistical comparison of cyclin D1 staining intensity between follicular, plexiform, and unicystic ameloblastomas Mann-Whitney test

| Types                | Groups compared | P value |
|----------------------|-----------------|---------|
| Follicular (group I) | Groups I and II | 0.3628  |
| Plexiform (group II) | Groups II and III | 0.4054  |
| Unicystic (group III)| Groups III and I | 0.7741  |

Table 4: Overall staining results and statistical comparison of staining intensity of both ameloblastomas and ademomatoid odontogenic tumors

| Types                                    | Intense | Moderate | Mild | Negative | Mann-Whitney test | P value |
|------------------------------------------|---------|----------|------|----------|-------------------|---------|
| Ameloblastoma (39 cases)                 | 3       | 12       | 16   | 8        |                   | 0.1744  |
| Adenomatoid odontogenic tumor (11 cases) | 0       | 2        | 5    | 4        |                   |         |

Hence the staining reaction analyzed was based on the majority of stained cells and the predominant staining intensity and localization were chosen in both the lesions.

**DISCUSSION**

Cyclins and CDKs play a central role in cell-cycle control and any alteration in them may lead to onogenesis.[13,11] Among the potentially oncogenic elements of the cell-cycle machinery, cyclin D1 is strongly implicated in onogenesis. Its fundamental role is to integrate mitogenic signals with the cell-cycle regulating system.[2]

In various studies, immunohistochemical expression of cyclin D1 in different tissue specimens is seen to be positively correlating with other proliferation markers such as Ki-67,[10] PCNA,[12] Topo II alpha, and histone H3 mRNA[9] and other cell-cycle regulatory proteins such as CDK4, p21, E2F1,[12] proapoptotic protein p53,[13] and inversely correlating with expression of tumor suppressor pRb protein[14], and bcl-2.[12] These studies supported the role of cyclin D1 as a potential marker of proliferation and onogenesis.

Information in the English language literature on cyclin D1 expression in ameloblastoma is quite sparse. In a comparative study of cyclin D1 expression between odontogenic keratocyst, dentigerous cyst, radicular cyst, and ameloblastoma, Vicente DJC et al., found diffuse expression in ameloblastoma, nuclear staining in parabasal cells of odontogenic keratocyst and sporadic expression in dentigerous cyst and radicular cyst supporting the role of cyclin D1 in proliferation of these odontogenic lesions.[15] Lo Muzio et al. also found expression of cyclin D1 in odontogenic keratocyst associated with nevoid-basal cell carcinoma syndrome, supporting odontogenic keratocyst’s neoplastic nature.[16] Kumamoto et al.[9] found sporadic expression of cyclin D1 in inner and outer enamel epithelium, stratum intermedium, stellate reticulum of tooth germs. Dental lamina showed little or no expression. Follicular and plexiform ameloblastomas showed cyclin D1 expression in many peripheral columnar or cuboidal cells and some central polyhedral cells.[9] Similar expression patterns of cyclin D1 in ameloblastoma were detected by Tanahashi et al., in their study of Wnt signaling molecules in this tumor.[17] In our study, the expression patterns of cyclin D1 in different histologic types of ameloblastomas were in line with these previous studies. However, the statistical analysis of intensity of staining between these different histologic types did not yield significant P values.

The predominant expression of cyclin D1 in both peripheral basal cells and central stellate reticulum-like cells suggests that basal cells possess a higher proliferative activity, supporting a finding by Stenmen et al.[13] Stellate reticulum-like cells unlike basal cells do not belong to the proliferative compartment. Hence cyclin D1 expression in these cells indicated its role in differentiation possibly by forming inactive complex with CDK2 and CDK5 helping cells to stabilize the differentiated state or to carry out cell-type-specific functions. Other possible explanation may be that the cyclin D1-CDK6 or CDK4 complex is inactivated by the simultaneous presence of a CDK inhibitor.[19] However, similar to Kumamoto et al.[9] we did not find cyclin D1 expression in terminally differentiated cells-like granular cell and squamous metaplastic cells in some follicular ameloblastomas. Further investigations are required in this regard to establish the role of cyclin D1 in differentiating odontogenic cells.

A search in the English language literature with key words “cyclin D1,” “adenomatoid odontogenic tumor,” and “immunohistochemistry” revealed no studies of cyclin D1 in the adenomatoid odontogenic tumor so far. However, in a study of PCNA, a proliferative marker, in adenomatoid odontogenic tumors, its expression was observed more in solid areas consisting of adenomatoid and duct-like structures similar to our findings with cyclin D1, indicating more proliferative activity in these areas.[20]

Though cyclin D1 predominantly expresses in nucleus, we found its immunoreactivity both in nucleus and cytoplasm and a combination of two. As cyclin D1 plays a role in proliferation and differentiation and the shift between nucleus and cytoplasm is necessary to regulate finely the passage across different phases of the cell cycle, immunogold studies have indicated its transition between nucleus and cytoplasm through nuclear pores.[21] Other possible reason is that cyclin D1 or its related CDK may be inactivated by being bound to further substrate and as a consequence loses its nuclear localization.[22] Even glycogen synthase kinase-3β (GSK-3β) exports cyclin D1 to the cytoplasm by facilitating cyclin D1 and exportin interaction or it might phosphorylate cyclin D1.
in cytoplasm preventing its association with proteins required for nuclear import.[23]

The heterogeneous staining pattern seen in our study in positive cases probably indicated that all cells might not be proliferating. The staining intensity also varied from mild to intense in the same section possibly due to variations in protein levels during cell-cycle progression.[1,5] Hence the predominant staining intensity was considered.

Though some cases of ameloblastoma showed intense and moderate staining indicating its distinctive clinical behavior compared to that in the adenomatoid odontogenic tumor, which predominantly showed mild staining, this did not reach statistical significance. Thus the marked expression of cyclin D1 suggested its participation in proliferation of both the tumors and its expression patterns were irrespective of their biologic behavior.

ACKNOWLEDGMENT

This study has been partly funded by Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka state, India.

REFERENCES

1. Wang TC, Cardiff RD, Zukerberg L, Lees E, Arnold A, Schmidt EV. Mammary hyperplasia and carcinoma in MMTV-Cyclin D1 transgenic mice. Nature 1994;369:669-71.
2. Todd R, Hinds PW, Munger K, Rustgi AK, Opitz OG, Suliman Y, et al. Cell cycle dysregulation in oral cancer. Crit Rev Oral Biol Med 2002;13:51-61.
3. Weinbern BI, Zhou P. Cell cycle control gene defects and human cancer. In: Bertino JR editor. Encyclopedia of Cancer. Vol. 1. California: Academic Press; 1997. p. 256-67.
4. Zuckerberg IR, Yang WI, Arnold A, Harris DL. Cyclin D1 expression in non Hodgkin’s lymphoma. Detection by immunohistochemistry. Am J Clin Pathol 1995;103:756-60.
5. Fracchiolla NS, Pruner G, Pignataro L, Carboni N, Capacccio P, Boletini A, et al. Molecular and immunohistochemical analysis of the bcl-1/Cyclin D1 gene in laryngeal squamous cell carcinomas: Correlation of protein expression with lymph node metastases and advanced clinical stage. Cancer 1997;79:1114-21.
6. Kuo MY, Lin C, Hahn LJ, Cheng SJ, Chiang CP. Expression of Cyclin D1 is correlated with poor prognosis in patients with areca quid chewing related oral squamous cell carcinomas in Taiwan. J Oral Pathol Med 1999;28:165-9.
7. Gillet C, Smith P, Gregory W, Richards M, Millis R, Peters G, et al. Cyclin D1 and prognosis in human breast cancer. Int J Cancer 1996;69:92-9.
8. Gardner DG, Heikinheimo K, Shear M, Philipsen HP, Coleman H. Ameloblastomas. In: Barnes L, Eveson JW, Reichart P, Sidransky D, editors. World Health Organisation classification of tumours–pathology and genetics of head and neck tumors. Lyon, France: IARC press; 2005. p. 296-300.
9. Kumamoto H, Kimi K, Ooya K. Detection of cell cycle-related factors in ameloblastomas. J Oral Pathol Med 2001;30:309-315.
10. Mate JL, Ariza A, Aracil C, López D, Isamat M, Pérez-Pitieira P, et al. Cyclin D1 overexpression in non-small cell lung carcinoma: Correlation with Ki-67 labeling index and poor cytoplasmic differentiation. J Pathol 1996;180:395-9.
11. Hinds P, Dowdy SF, Eaton EN. Arnold A, Weinberg RA. Function of a human Cyclin gene as an oncogene. Proc Natl Acad Sci 1994;91:709-13.
12. Staibano S, Mignogna MD, Lo Muzio L, Di Alberti L, Di Natale E, Lucariello A, et al. Over expression of Cyclin D1, Bcl-2 and bax proteins, proliferating cell nuclear antigen (PCNA), and DNA-Ploidy in squamous cell carcinoma of the oral cavity. Hum Pathol 1998;29:1189-95.
13. Lam KY, Ng IO, Yuen AP, Kwong DL, Wei W. Cyclin D1 expression in oral squamous cell carcinomas: Clinicopathological relevance and correlation with p53 expression. J Oral Pathol Med 2000;29:167-72.
14. Etges A, Nunes FD, Reibero KC, Araújo VC. Immunohistochemical expression of retinoblastoma pathway proteins in normal salivary glands and in tumors of salivary glands. Oral Oncol 2004;40:326-31.
15. de Vicente JC, Torre-Itruraspe A, Gutiérrez AM, Lequerica-Fernández P. Immunohistochemical comparative study of the odontogenic keratocysts and other odontogenic lesions. Med Oral Patol Oral Cir Bucal 2010;15: e709-15
16. Lo Muzio L, Staibano S, Pannone G, Bucci P, Nocini PF, Bucci E, et al. Expression of cell cycle and apoptosis-related proteins in sporadic odontogenic keratocysts and odontogenic keratocysts associated with the nevoid basal cell carcinoma syndrome. J Dent Res 1999;78:1345-53.
17. Tanahashi J, Daa T, Yada N, Kashima K, Kondoh Y, Yokoyama S. Mutational analysis of Wnt signaling molecules in ameloblastoma with aberrant nuclear expression of beta-catenin. J Oral Pathol Med 2008;37:565-70.
18. Stenman G, Lilia J, Sagne S. Human ameloblastomas “in vitro”: Light microscopical and ultrastructural observations. Br J Oral Maxillofac Surg 1985;23:326-32.
19. Gao CY, Zelenka PS. Cyclins, cyclin-dependent kinases and differentiation. Bioessays 1997;19:307-15.
20. Crivelini MM, Soubbia AM, Felipini RC. Study on the origin and nature of adenomatoid odontogenic tumor by immunohistochemistry. J Appl Oral Sci 2005;13:406-12.
21. De Falco M, Fedele V, De Luca L, Penta R, Cottone G, Cavallotti I, et al. Molecular and immunohistochemical analysis of the bcl-1/Cyclin D1 gene in laryngeal squamous cell carcinomas: Correlation of protein expression with lymph node metastases and advanced clinical stage. Cancer 1997;79:1114-21.
22. Tut VM, Braithwaite KL, Angus B, Neal DE, Luneç J, Mellon JK. Cyclin D1 expression in transitional cell carcinoma of the bladder: Correlation with p53, waf1, pRb and Ki67. Br J Cancer 2001;84:270-5.
23. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3β regulates Cyclin D1 proteolyis and subcellular localization. Genes Dev 1998;12:3499-511.

How to cite this article: Kumar H, Vandana R, Kumar GS. Immunohistochemical expression of cyclin D1 in ameloblastomas and adenomatoid odontogenic tumors. J Oral Maxillofac Pathol 2011;15:283-7.

Source of Support: Partly funded by Rajiv Gandhi University of Health Sciences, Bangalore, Karnataka state, India. Conflict of Interest: None declared.